Searching Biomarkers of Acute Intestinal Ischemic Injuries
Survibio
1 other identifier
interventional
556
1 country
1
Brief Summary
The aim of the SURVIBIO study is to characterize accurate biomarkers for acute mesenteric ischemia, in particular at early stages. In the study, the development of biomarkers will be based on the analysis of human biological samples from patients and controls that will be conserved in a biological library. Samples will be analysed in the Laboratory for Vascular Translational Sciences (LVTS, Inserm U1148), in the Department of Biochemistry (Pr Puy, Dr Peoc'h), in Paris V university , in Imperial College of London (Pr Dumas), in Jacques Monod Institute and in Maastricht University Medical Center . The candidate markers will be determined according to an a priori method (form markers already described in the literature) and with no a priori strategy using -omics methods.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Nov 2018
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 25, 2018
CompletedFirst Posted
Study publicly available on registry
May 8, 2018
CompletedStudy Start
First participant enrolled
November 16, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 30, 2028
December 16, 2025
December 1, 2025
9.1 years
April 25, 2018
December 8, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
observation of clinical-bio-scanographic pain related to a splanchnic-mesenteric, occlusive or non-occlusive vascular insufficiency, to abdominal CT angiography, in the absence of another identifiable cause
2 years
Secondary Outcomes (5)
mortality and causes
2 years
Intestinal resection ratio
2 years
acute intestinal ischemic injury relapse ratio
2 years
short gut syndrome features
2 years
persistency of mesenteric ischemia clinical signs or of ischemic gastric stenosis
2 years
Study Arms (2)
Patient
EXPERIMENTALAny patient admitted for acute abdomen condition with or without ischemic causes.
witness
EXPERIMENTALInterventions
Two tubes of 5ml of blood will be collected for Serum collection, 3 tubes of 5 ml of blood taken for plasma collection and 2 tubes of 7 ml of blood taken for DNA collection
Eligibility Criteria
You may qualify if:
- age\> 18 years
- Acute abdominal pain requiring an injected abdominal injected CT scan, at best at non-injected / early arterial / portal time
- Admitted or attended in Beaujon and / or Bichat hospitals
- Patient covered by a social security scheme
- Written consent
You may not qualify if:
- lack of abdominal CT scan
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Corcos Olivier
Clichy, France
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 25, 2018
First Posted
May 8, 2018
Study Start
November 16, 2018
Primary Completion (Estimated)
December 31, 2027
Study Completion (Estimated)
July 30, 2028
Last Updated
December 16, 2025
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will share